NASDAQ:RIGL Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free RIGL Stock Alerts $1.13 +0.05 (+4.63%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$1.06▼$1.1450-Day Range$1.05▼$1.5752-Week Range$0.71▼$1.96Volume3.34 million shsAverage Volume1.46 million shsMarket Capitalization$198.20 millionP/E RatioN/ADividend YieldN/APrice Target$5.81 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Rigel Pharmaceuticals alerts: Email Address Rigel Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside414.4% Upside$5.81 Price TargetShort InterestBearish2.86% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.05) to $0.05 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.10 out of 5 starsMedical Sector771st out of 910 stocksPharmaceutical Preparations Industry359th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingRigel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageRigel Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.86% of the outstanding shares of Rigel Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRigel Pharmaceuticals has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Rigel Pharmaceuticals has recently increased by 1.42%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRigel Pharmaceuticals does not currently pay a dividend.Dividend GrowthRigel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RIGL. Previous Next 0.6 News and Social Media Coverage Search Interest7 people have searched for RIGL on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.43% of the stock of Rigel Pharmaceuticals is held by insiders.Percentage Held by Institutions66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rigel Pharmaceuticals are expected to grow in the coming year, from ($0.05) to $0.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rigel Pharmaceuticals is -7.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rigel Pharmaceuticals is -7.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Rigel Pharmaceuticals Stock (NASDAQ:RIGL)Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Read More RIGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RIGL Stock News HeadlinesApril 10, 2024 | prnewswire.comRigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)April 4, 2024 | prnewswire.comRigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & LymphomaApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 16, 2024 | finance.yahoo.comRIGL Apr 2024 3.000 callMarch 12, 2024 | finanznachrichten.deRigel Pharmaceuticals, Inc.: Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical OfficerMarch 12, 2024 | markets.businessinsider.comRigel Pharma Names Rojkjaer EVP, Chief Medical OfficerMarch 12, 2024 | prnewswire.comRigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical OfficerMarch 7, 2024 | finance.yahoo.comRigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the YearApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 7, 2024 | insidermonkey.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | barrons.comRigel Pharmaceuticals Inc.March 6, 2024 | stockhouse.comRigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | benzinga.comRigel Pharmaceuticals: Q4 Earnings InsightsMarch 6, 2024 | markets.businessinsider.comRigel Pharmaceuticals Inc. Q4 Earnings SummaryMarch 6, 2024 | msn.comRigel Pharmaceuticals GAAP EPS of $0.00 beats by $0.02, revenue of $35.8M beats by $2.39MMarch 6, 2024 | finance.yahoo.comOwning 47% shares,institutional owners seem interested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL),March 6, 2024 | finance.yahoo.comQ4 2023 Rigel Pharmaceuticals Inc Earnings CallMarch 6, 2024 | gurufocus.comQ4 2023 Rigel Pharmaceuticals Inc Earnings Call TranscriptMarch 5, 2024 | investorplace.comRIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023February 27, 2024 | prnewswire.comRigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business UpdateFebruary 26, 2024 | seekingalpha.comRigel Pharmaceuticals: Gavreto Deal Expands Growth ProspectsFebruary 23, 2024 | markets.businessinsider.comBuy Rating for Rigel: Strategic Acquisitions and Market Positioning Fuel Revenue Growth PotentialFebruary 23, 2024 | finance.yahoo.comRIGL Mar 2024 1.500 putFebruary 22, 2024 | benzinga.comRigel Pharmaceuticals Stock (NASDAQ:RIGL), Short Interest ReportFebruary 22, 2024 | markets.businessinsider.comRigel Pharma Acquires US Rights To Gavreto From Blueprint Medicines; Stock Up In Pre-MarketFebruary 22, 2024 | finance.yahoo.comRigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®February 22, 2024 | prnewswire.comRigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®See More Headlines Receive RIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today4/23/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:RIGL CUSIP76655960 CIK1034842 Webwww.rigel.com Phone(650) 624-1100Fax650-624-1101Employees147Year Founded1996Price Target and Rating Average Stock Price Target$5.81 High Stock Price Target$15.00 Low Stock Price Target$1.25 Potential Upside/Downside+414.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,090,000.00 Net Margins-21.47% Pretax Margin-21.47% Return on EquityN/A Return on Assets-21.21% Debt Debt-to-Equity RatioN/A Current Ratio1.86 Quick Ratio1.76 Sales & Book Value Annual Sales$116.88 million Price / Sales1.70 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-7.06Miscellaneous Outstanding Shares175,400,000Free Float164,126,000Market Cap$198.20 million OptionableOptionable Beta0.95 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Raul R. Rodriguez (Age 63)President, CEO & Director Comp: $1.09MMr. Dean L. Schorno CPA (Age 61)Executive VP & CFO Comp: $696.67kMr. Raymond J. Furey J.D. (Age 56)Executive VP, General Counsel & Corporate Secretary Comp: $593.46kMr. David A. Santos (Age 61)Executive VP & Chief Commercial Officer Comp: $681.63kMs. Julie PatelSenior VP of Human ResourcesDr. Esteban S. Masuda (Age 62)Executive Vice President of Research Comp: $537.21kMr. Joseph Lasaga (Age 49)Executive VP & Chief Business Officer Dr. Lisa Rojkjaer M.D. (Age 58)Executive VP & Chief Medical Officer Mr. Tarek SallamVice President of MarketingMore ExecutivesKey CompetitorsRegulus TherapeuticsNASDAQ:RGLSVanda PharmaceuticalsNASDAQ:VNDAVerastemNASDAQ:VSTMXOMANASDAQ:XOMAEmergent BioSolutionsNYSE:EBSView All CompetitorsInstitutional OwnershipLos Angeles Capital Management LLCBought 198,712 shares on 4/5/2024Ownership: 0.344%Armistice Capital LLCSold 36,000 shares on 2/13/2024Ownership: 9.807%Russell Investments Group Ltd.Sold 47,719 shares on 2/5/2024Ownership: 0.083%View All Institutional Transactions RIGL Stock Analysis - Frequently Asked Questions Should I buy or sell Rigel Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RIGL shares. View RIGL analyst ratings or view top-rated stocks. What is Rigel Pharmaceuticals' stock price target for 2024? 4 brokerages have issued twelve-month price objectives for Rigel Pharmaceuticals' shares. Their RIGL share price targets range from $1.25 to $15.00. On average, they predict the company's share price to reach $5.81 in the next twelve months. This suggests a possible upside of 414.4% from the stock's current price. View analysts price targets for RIGL or view top-rated stocks among Wall Street analysts. How have RIGL shares performed in 2024? Rigel Pharmaceuticals' stock was trading at $1.45 at the start of the year. Since then, RIGL stock has decreased by 22.1% and is now trading at $1.13. View the best growth stocks for 2024 here. When is Rigel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our RIGL earnings forecast. How were Rigel Pharmaceuticals' earnings last quarter? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) posted its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.04. The biotechnology company earned $28.13 million during the quarter, compared to analysts' expectations of $27.83 million. During the same quarter in the previous year, the business posted ($0.11) EPS. What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO? 6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees. What other stocks do shareholders of Rigel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). Who are Rigel Pharmaceuticals' major shareholders? Rigel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.34%). Insiders that own company stock include David A Santos, Dean L Schorno and Raul R Rodriguez. View institutional ownership trends. How do I buy shares of Rigel Pharmaceuticals? Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RIGL) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
